Concepedia

Author

Zefei Jiang

Chinese PLA General HospitalORCID

Also Known As

CSCO BC guideline working group, Garber, J., Jiang Z, Jiang, Z., Min Li, Ying Mao, Z F Jiang, Z Jiang, Z. F. Jiang, Z. Jiang

372

Publications

15.3K

Citations

46

H-Index

60

Concepts

All Affiliations

Chinese PLA General HospitalFudan University Shanghai Cancer CenterAcademy of Military Medical SciencesSun Yat-sen UniversityHarbin Medical University
ZJ

About

Zefei Jiang is an author at Chinese PLA General Hospital specializing in medicine, breast cancer, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

24

40

6.8K

2

Health Sciences

8

8

4.8K

3

Engineering

1

1

14

4

Nursing

1

1

3.6K

5

Public Health

1

1

113

Zefei Jiang

×

99

Publications

13.7K

Citations

42

H-Index

YearCitations

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

Aron Goldhirsch, Eric P. Winer, Alan S. Coates,

Annals of Oncology

2013

3.6K

Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

Alan S. Coates, Eric P. Winer, Aron Goldhirsch,

Annals of Oncology

2015

1.8K

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

Giuseppe Curigliano, Harold J. Burstein, Eric P. Winer,

Annals of Oncology

2017

1.2K

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen,

The Lancet Oncology

2017

578

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

José Baselga, Seock‐Ah Im, Hiroji Iwata,

The Lancet Oncology

2017

532

Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer

Harold J. Burstein, Yan Sun, Luc Dirix,

Journal of Clinical Oncology

2010

523

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

Nadia Harbeck, Priya Rastogi, Miguel Martín,

Annals of Oncology

2021

364

Pyrotinib or Lapatinib Combined With Capecitabine in HER2–Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study

Fei Ma, Quchang Ouyang, Wěi Li,

Journal of Clinical Oncology

2019

335

Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial

Sara A. Hurvitz, Fabrice André, Zefei Jiang,

The Lancet Oncology

2015

300

Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer

Xichun Hu, Jian Zhang, Binghe Xu,

International Journal of Cancer

2014

267

Page 1